Precision medicine for lysosomal disorders

• Autor(a) principal: Vairo, Filippo Pinto e
• Data de Publicação: 2020
• Outros Autores: Málaga, Diana Elizabeth Rojas, Kubaski, Francyne, Souza, Carolina Fischinger Moura de, Poswar, Fabiano de Oliveira, Baldo, Guilherme, Giugliani, Roberto
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFRGS
• Texto Completo: http://hdl.handle.net/10183/214122
• topic: Doenças por armazenamento dos lisossomos; Erros inatos do metabolismo; Medicina de precisão; Terapia de reposição de enzimas; Terapia genética; Lysosomal diseases; Precision medicine; Enzyme replacement therapy; Pharmacological chaperones; Gene therapy

Precision medicine (PM) is an emerging approach for disease treatment and preventionthat accounts for the individual variability in the genes, environment, and lifestyle of each person.Lysosomal diseases (LDs) are a group of genetic metabolic disorders that include approximately70 monogenic conditions caused by a defect in lysosomal function. LDs may result from primarylysosomal enzyme deficiencies or impairments in membrane-associated proteins, lysosomal enzymeactivators, or modifiers that affect lysosomal function. LDs are heterogeneous disorders, and thephenotype of the affected individual depends on the type of substrate and where it accumulates,which may be impacted by the type of genetic change and residual enzymatic activity. LDs areindividually rare, with a combined incidence of approximately 1:4000 individuals. Specific therapiesare already available for several LDs, and many more are in development. Early identification mayenable disease course prediction and a specific intervention, which is very important for clinicaloutcome. Driven by advances in omics technology, PM aims to provide the most appropriatemanagement for each patient based on the disease susceptibility or treatment response predictionsfor specific subgroups. In this review, we focused on the emerging diagnostic technologies that mayhelp to optimize the management of each LD patient and the therapeutic options available, as well asin clinical developments that enable customized approaches to be selected for each subject, accordingto the principles of PM.